Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

18th International Meeting of the European Society of Gynaecological Oncology (ESGO) /
Results from the TRINOVA 1 trial

19th - 22nd Oct 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.11.13
Views: 3662

Prof Bradley Monk - Creighton University School of Medicine, USA

Prof Bradley Monk talks to ecancer at the 2013 ESGO meeting in Liverpool about a phase III, randomised trial with pacitaxel plus trebanaib in recurrent ovarian cancer.

Trebananib is an anti-angiogenesis peptibody that inhibits the binding of angiopoietin 1/2 to the Tie2 receptor. The trial reported that trebananib prolonged progression free survival by 52% and had an increased response rate from 30% to 38%.


ecancer's filming at ESGO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.



Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation